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Introduction
Endoscopic mucosal resection (EMR) and endoscopic submuco-
sal dissection (ESD) are widely used in the West as therapeutic
methods for resection of non-polypoid lesions of the gastroin-
testinal tract. The most effective and simplest way to prevent
adverse events during EMR and ESD is to create a sufficiently
thick submucosal layer by endoscopic injection of fluid into
the submucosa [1]. Sodium hyaluronic acid is commonly used
in Japan to carry out ESD whereas in Western countries differ-
ent solutions are available [2, 3].
In a recent comparative study of the submucosal injection
fluids currently available in the West, a volume expander (6%
hydroxyethyl starch) and Eleview (a mixture of medium chain
triglycerides, poloxamer 188, polyoxyl-15-hydroxystearate, so-
dium chloride and methylene blue) were the best-performing
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ABSTRACT
Background and study aims Endoscopic resection re-
quires use of submucosal injection. This study was conduct-
ed to assess efficacy and impact on early healing of hyaluro-
nic acid combined with chondroitin sulfate and poloxamer
407 (Ziverel) when used as a solution for submucosal injec-
tion.
Materials and methods Prospective and comparative
study of gastric endoscopic mucosal resection (EMR) with
three groups of two Yorkshire pigs. Six submucosal cush-
ions were created in each animal by injecting 2mL of Ziverel
(Group 1) or succinylated gelatin (SG) (Group 2), enabling
12 EMR in each group. Submucosal cushions were created
with Ziverel in Group 3, without resection. Electrosurgery
unit settings were the same in all cases. EMR defects and in-
jection sites were marked with clips. The animals were sa-
crificed 7 days later. EMR specimen size and duration of pro-
cedure were recorded. EMR specimens and EMR scars and
injection sites were evaluated by a blinded pathologist.
Results We successfully performed 24 EMR (15 en-bloc
and 9 piecemeal, without differences between groups 1
and 2). Mean EMR specimen dimensions were significantly
larger in Group 1 (median 19mm, range 6–40 vs 16.6mm,
range 5‑25; P=0.019), without changing the electrocautery
unit settings. Blinded histopathologist assessment of EMR
specimens showed less fibrosis in the submucosa and a
trend to fewer cautery artifacts with Ziverel and did not
identify any significant differences in early healing of resec-
tion sites.
Conclusion The combination of Ziverel enables EMR and
does not negatively affect early healing.
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solutions for ESD in a porcine model [4]. Moreover, an ideal so-
lution should be inexpensive and without potential damage of
the resected specimen or early healing impairment.
Recently, we have reported that a new treatment for gastro-
esophageal reflux that combines hyaluronic acid, chondroitin
sulfate and poloxamer 407 (Ziverel) could be used as a solution
for submucosal injection because it creates a long-lasting cush-
ion, does not induce acute tissue damage and it is not expen-
sive [5].
The objective of this study was to assess the efficacy and im-
pact on early healing of Ziverel as submucosal injection solution
for EMR compared with succinylated gelatin (SG), which is the
standard solution used in our Unit.
Materials and methods
This prospective and comparative study was conducted with six
Yorkshire pigs allocated into three groups: EMR with Ziverel
(Norgine, UK) (Group 1, n =2), EMR with SG (Gelafundin, Braun
Medical, Spain) (Group 2, n=2) and injection of Ziverel without
resection (Group 3, n=2). Gastroscopy was conducted with the
animals under general anesthesia and all the procedures were
performed by a single endoscopist who was not blinded to
which solution was injected.
Six submucosal cushions were created in each animal by in-
jecting 2mL of solution with a 23-gauge catheter injection nee-
dle (Interject, Boston Scientific Corp., Marlborough, Massachu-
setts, United States). Ziverel was diluted with saline solution at
a concentration of 50% to ease the injection [4]. In Groups 1
and 2, a total of 24 EMR were performed (12 in each group)
using a 25-mm polypectomy snare (SD-210U-25, Olympus
Medical Systems Corp., Tokyo, Japan). Each EMR was the largest
possible safe en-bloc or piecemeal resection. An ERBE electro-
surgery unit was used (VIO 300D, ERBE Co, Tübingen Germany)
with the same settings (ENDOCUT Q mode, effect 3, duration 1,
interval 6) in all cases. A 2-mL injection volume was chosen be-
cause preliminary experimentation showed that a larger vol-
ume resulted in a bleb that did not fit into the snare. At the
end of the procedure, EMR defects and injection sites were
marked with clips (▶Fig. 1) and retrieved EMR specimens were
pinned to a cork board (▶Fig. 2).
EMR specimen size was measured (maximal length × maxi-
mal width) and EMR duration was measured by time and num-
ber of pulses of Endocut needed to completion of snare resec-
tion. Note was made of systematic adverse effects, bleeding or
perforation.
Animals were observed daily for 6 days and were sacrificed
on day 7. The stomachs were retrieved and opened to find the
remaining clips, and abdominal cavities were inspected. Sto-
machs and EMR specimens were fixed with formalin. Selected
sections from each area marked with clips or mucosal lesion
were cut and processed to obtain formalin-fixed paraffin-em-
bedded tissue blocks. From each paraffin block, 2-µm-thick his-
tological sections were stained with hematoxylin and eosin
(H&E) and examined with a conventional Olympus BX41 micro-
scope (Olympus, Tokyo, Japan) by a pathologist blinded to the
solution used. Pathological features such as reepithelization
was scored as 0= absence and 1=presence, while fibrosis and
acute and chronic inflammation were semi-quantitatively
scored as 0=absence; 1 mild; 2 intermediate; 3 high. Thickness
of the submucosa in the resected specimen and the granulation
tissue were measured in mm.
The study was approved by the Ethics Animal Committee of
Barcelona University.
▶ Fig. 1 EMR defects and injection sites marked with clips.
▶ Fig. 2 Retrieved EMR specimens pinned to cork.
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Statistical analysis
Quantitative variables are expressed as median plus range. Sta-
tistical comparisons between groups 1 and 2 were made by
using the Mann-Whitney non-parametric test. A P value <0.05
was considered significant. Calculations were performed with
SPSS software (SPSS 21.0 for Windows, SPSS, Inc., Chicago, Illi-
nois, United States).
Results
We successfully performed 24 EMRs (15 en-bloc and 9 piece-
meal). The median EMR specimen maximal length was signifi-
cantly larger in Group 1 than in Group 2 (19mm, range 6–40
vs 16.5mm, range 5–25; P=0.019). Using the same electro-
cautery unit settings, mean time upon completion of all EMR
was not different between groups (▶Table1). No perforation
or intraprocedural hemorrhage was observed. Animals recov-
ered well and gained weight (median 29.4 kg, range 27.9–
20.6 vs 32 kg, range 29.9–33.9).
Microscopic examination of the EMR specimens showed a
thicker submucosa with edema and a trend to fewer cautery-
related artifacts in Group 1 (▶Table2, ▶Fig. 3). The muscularis
propria was not visible in any specimen.
We could identify the 24 EMR scars in the gastrectomy speci-
mens at the time of necropsy. Histological assessment of the
scars did not show any significant differences between Group1
and 2, except for more fibrotic changes in the latter (▶Table 3,
▶Fig. 4). With regards to the stomachs in Group 3, only mild fi-
brosis and chronic inflammation were identified. These findings
are commonly described in pigs’ normal gastric mucosa (▶Ta-
ble4).
Discussion
In this study, we compared a new treatment for gastroesopha-
geal reflux that combines hyaluronic acid, chondroitin sulfate,
and poloxamer 407 with a common solution used for submuco-
sal injection and evaluated their impact on the outcomes of
gastric EMR and early healing in pigs. Use of the new substance
was associated with larger and deeper EMR specimens and few-
er cautery artifacts, and did not negatively affect early healing
or cause any long-term injury in the normal gastric wall.
SG was used as a control injection substance because it is
used for performing EMR in our unit due to its durability, wide
availability in our country and low price. Moreover, SG provides
EMR specimens with larger surface area than with normal saline
solution [3]. Compared with SG, Ziverel provided a better cir-
cumscribed elevation that facilitated tissue capture with the
snare and a larger specimen.
The capability of Ziverel to separate the mucosal layer from
the muscularis propria by increasing the thickness of the sub-
mucosa due to edema was already demonstrated in the pilot
study performed by our group [5]. Poloxamer 407, which is
one of the compounds of Ziverel, is a reverse phase polymer
that becomes gel at body temperature, breaking and replacing
the connective tissue. Having a thick submucosa layer included
in the resected specimen is of paramount importance because
it increases the chance of performing a curative resection with
free margins, even in the case of deep infiltration of the super-
ficial submucosa.
It is of crucial importance to achieve en bloc resection of
colorectal laterally spreading tumors or early gastrointestinal
neoplasia, because en bloc resection is associated with a low lo-
cal recurrence rate [6, 7]. In the last few years, endoscopic sub-
mucosal dissection (ESD) has emerged as an alternative to EMR
when lesions are big and it is not possible to perform en bloc re-
sections. However, piecemeal EMR is still the standard of care in
several countries, but even in that case, it is preferable to obtain
large specimens to decrease the number of pieces [8]. Al-
though with Ziverel the rate of en bloc EMR was not different
from SG, the size of the resected specimens was larger.
Damage to the resected specimen, either by piecemeal re-
section or by cauterization artifacts, can limit precise histologi-
cal diagnosis of a targeted lesion, and hyaluronic acid has
shown to be the least harmful [9]. Furthermore, damage to the
muscle layer may result in delayed bleeding or perforation. The
addition of poloxamer to hyaluronic acid used in the current
study did not damage the mucosa of the EMR specimen, con-
firming its safety, but even more important was the fact that
cautery damage of the borders was less evident than with SG.
The impact of potential solutions for submucosal injection
on resected ulcer healing has been evaluated in several studies
▶ Table 1 Technical and macroscopic characteristics of EMR.
Group 1
(ZiverelR)
Group 2
(SG)
P value
All EMR
N=12
En-bloc
N=7
All EMR
N=12
En-bloc
N=8
All En-bloc
Maximal length (mm) 19 (6–40) 19 (17–40) 16.5 (5–25) 16.5 (5–22) 0.019 0.035
Maximal width (mm) 16 (5–32) 15 (13–32) 12.5 (3–19) 10 (3–19) 0.060 0.041
Time (minutes) 10.6 (1.5–19.7) 8.5 (1.5 –19.7) 10.2 (3.4–19.7) 9.2 (3.4–19.7) 0.95 0.972
Endocut pulses 9.5 (3–15) 7 (3– 15) 8.5 (4–18) 7.5 (4 –18) 0.8 0.994
EMR, endoscopic mucosal resection.
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and glycerol has shown more pronounced histological signs of
early healing [10]. In our study, Ziverel showed an early healing
that was no different from SG, except for less fibrosis that could
be explained by changes in permeability of injured mucosa
[11]. Based on these properties, we hypothesize that Ziverel
could also facilitate the healing process of the scar left after
EMR or ESD and expect an early proliferation of collagen and
elastic fibers as described with other solutions [10, 12].
▶ Fig. 3 a Microscopic examination of the EMR specimens showing less mucosal cautery-related artifacts in the Ziverel group b than with SG,
where the epithelial glands are not visible and architecture is lost. The muscularis propria is not visible in any specimen.
▶ Fig. 4 a (1) Gross appearance of the scars with larger mucosectomy area with Ziverel b than SG. a (2) Microscopic examination of the scars–
red arrows- shows residual superficial edema (red line) and less submucosal fibrosis (yellow line) with Ziverel b compared with SG. In this latter,
there is no residual edema and thicker and more fibrotic changes in the submucosal scar. 3) Reepithelization is seen in both groups (red ar-
rows), being more evident in a Ziverel group.
E580 Córdova H. et al. Successful outcomes of… Endoscopy International Open 2019; 07: E576–E582
Original article
The use of solutions with high osmolality, such as hypertonic
saline solution or 20% to 50% dextrose water, induces acute
mucosal damage consisting of erosion and congestion of capil-
lary blood vessels that is persistent a week after injection, in the
form of submucosal fibrosis [13]. Ziverel is also a hyperosmotic
solution with around 2,000 mOsm/L but contrarily, was not
associated with any significant abnormality in the gastric wall
1 week after the injection.
Another interesting result is that the new solution did not af-
fect the speed of EMR. Using the same settings of the electro-
surgical unit as with SG, there were no differences regarding in
time needed to complete EMR. These results are consistent
with the initial experience with poloxamer [14].
Among available submucosal injection solutions in clinical
practice, so far the most suitable for producing a long-lasting
cushion is high-molecular-weight hyaluronic solution [15].
However, the crucial disadvantage of hyaluronic acid in current
formulations is the high cost, which limits its use in many coun-
tries. Therefore, the combination of hyaluronic acid with Gly-
ceol has been proposed as an acceptable low-cost alternative
[15]. Interestingly, the cost of Ziverel is significantly lower
than hyaluronic acid alone (0.10 and 11.84 USD per mL, respec-
tively) and very similar to Gelafundin (0.08 USD per mL). There-
fore, its use could decrease the final cost of the procedure,
making its use widely available.
This study has the strength that the pathologist was blind to
the solution used. The endoscopist knew which solution was
tested, as noticeable differences in viscosity of the two solu-
tions during the injection and the consistency of the blebs
made endoscopist blinding impractical.
With regard to limitations, we only injected 2mL of solution,
which is far from the usual amount needed for a large EMR. We
chose this amount because the consistency of the bleb made it
impossible to catch a larger bleb with a 25-mm snare.
Conclusion
In conclusion, the current study demonstrates that the combi-
nation of hyaluronic acid, chondroitin sulfate, and poloxamer
407 enables EMR and does not negatively affect early healing.
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